I recently had the opportunity to read some of the proceedings from the 2014 Society of Interventional Radiology (SIR) Annual Scientific Meeting and thought that the excitement surrounding the nascent field of interventional oncology is palpable. As a practicing medical oncologist who manages the often complex needs of patients with gastrointestinal malignancies, I have experienced first-hand the rapid expansion of diagnostic and therapeutic options provided for these patients by our interventional radiology colleagues. In 2014, interventional oncology has indeed evolved to be the "fourth leg of the cancer treatment stool," or table, as it were. Welcome to the table! My own oncology practice, which principally includes patients with hepatocellular carcinoma (HCC), is a testament to integration of the panoply of interventional radiology procedures into state-of-the-art cancer treatment. Without the support and services of superb interventional radiologists, it is simply not possible to adequately care for patients with complicated HCC. In early 2011, my colleague Marcelo Guimaraes, MD, proposed that we create a joint hepatobiliary clinic. During this weekly combined interventional radiology-gastrointestinal oncology clinic, we concurrently evaluate and manage patients with HCC, cholangiocarcinoma, metastatic colorectal cancer, and neuroendocrine tumors. The goal of this clinic is to ensure close coordination of patient care, consistent incorporation of the best medical evidence into treatment decisions, and access to clinical trials when appropriate.
We can encourage a positive outlook and support spiritual beliefs, but patients want facts to weigh in their decision-making. When the best possible evidence of benefit does not exist or is weak or conjectural, then oncologists are left with a void in our conversation and our relationship with patients that cannot be filled with empty promises.
In my view, a "seat at the table" for interventional oncology comes with the obligation to expend the time, effort, and resources to consistently conduct prospective, controlled, adequately-powered research studies that demonstrate the benefits and risks of interventional oncology-proffered treatments to a degree of certainty expected of new chemotherapy drugs. Our patients, your patients, deserve nothing less.
